semaj83/ctmatch_classification huggingface dataset:
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diarrhea Adult male or nonpregnant female aged ≥18 years non-indigenous travelers (for example; visiting students/faculty or international tourists) affected by naturally acquired acute diarrhea. Diarrhea is defined as the passage of at least 3 unformed stools in a 24-hour period. Stools are classified as formed (retains shape), soft (assumes shape of container), or watery (can be poured). When using this classification, both soft and watery stools are unformed and abnormal. 2. At least 3 unformed stools recorded within the 24 hours immediately preceding randomization. 3. At least 1 of the following signs and symptoms of enteric infection abdominal pain or cramps nausea vomiting fecal urgency excessive gas/flatulence tenesmus 4. Women of child-bearing potential have a negative pregnancy test prior to beginning therapy and agree to use effective contraceptive methods during the study  Pregnant, breast feeding, or planning a pregnancy. 2. Immediately prior to randomization, acute diarrhea for >72 hours. 3. Presence of fever (≥100 degrees fahrenheit [°F] or ≥37.8 degrees celsius [°C]), or hematochezia (blood in stool), or clinical findings suggesting moderate or severe dehydration. 4. Active, uncontrolled, or clinically significant diseases or disorders of the heart, lung, kidney, gastrointestinal (GI) tract (other than infectious diarrhea in travelers), or central nervous system. 5. Administration of any of the following any antimicrobial agents with an expected activity against enteric bacterial pathogens within 7 days preceding randomization more than 2 doses of a symptomatic antidiarrheal compound such as antimotility agents, absorbent agents, and antisecretory agents within 8 hours preceding randomization 6. Use of any drug such as aspirin or ibuprofen (Advil), which can cause GI bleeding. Acetaminophen (Tylenol) or paracetamol is acceptable
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 1.0-40.0,  Cholera Subject willing to provide written informed consent to study participation voluntarily provided by an individual or his/her legally acceptable representative. 2. Individuals aged 1 years. 3. An individual who can be followed up during the study period and is capable of complying with the study requirements  Known history of hypersensitivity reactions to other preventive vaccines. 2. Known history of immune function disorders including immunodeficiency diseases, or chronic use of systemic steroids (> 20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic drugs or other immunosuppressants. 3. Severe chronic diseases, based on the judgment of the investigator. 4. 38℃ or higher body temperature measured prior to investigational product dosing. 5. Abdominal pain, nausea, vomiting, or decreased appetite within 24 hours prior to study initiation. 6. Diarrhea or administration of antidiarrheal drugs or antibiotics to treat diarrhoea within 1 week prior to study initiation. 7. Diarrhea or abdominal pain lasting 2 weeks or longer within 6 months prior to study initiation. 8. Other vaccination within 1 week prior to study initiation or planned vaccination during the study, except for tetanus toxoid vaccine. 9. Participation in another clinical trial with investigational product dosing within 1 month prior to study initiation. 10. Pregnant or lactating women, women of reproductive age planning pregnancy and/or lactation before the end of the study period. 11. An individual thought to have difficulty participating in the study due to other reasons, based on the judgment of the investigator 12. History of cholera vaccinations or history of cholera. 13. History of alcohol or substance abuse 14. Participant planning to move from the study area before the end of study period
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Abdominal Pain Diarrhea Hematochezia Patients who repeatedly have the symptom such as abdominal pain, diarrhea, hematochezia and so on, or Patients who volunteer to the colonoscopy screening  Dysphagia or swallowing disorder Congestive heart failure Renal insufficiency Prior major abdominal surgery of the gastrointestinal tract Known or suspected bowel obstruction Presence of a cardiac pacemaker or other implanted electromedical devices Allergy or contraindication to the medications used in the study
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Evaluation of Test Panel Whole blood (prospectively collected via informed consent) Adult subject has a recorded or self-reported fever within the previous 24 hours Subject provides informed consent prior to enrollment and specimen collection Subject has not previously provided a whole blood specimen for this study Whole blood (residual) Whole blood (in EDTA) submitted to laboratory for standard of care testing Specimen is not from an individual with a specimen previously enrolled in the study Positive Blood Culture Culture was detected as positive by an automated blood culture system Culture is not from a patient previously enrolled in the study Negative Blood Culture Culture not detected as positive by an automated blood culture system Culture is not from a patient previously enrolled in the study Sputum
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Irritable Bowel Syndrome With Constipation Patient has completed a colonoscopy according to the American Gastroenterological Association (AGA) with no clinically significant findings Patient has no clinically significant findings on a physical examination and clinical laboratory tests Patient meets protocol for diagnosis of IBS-C Patient demonstrates continued IBS-C through Pretreatment Period Patient maintains a minimum level of compliance with daily diary  Patient has history of loose or watery stools Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection C. difficile infection defined as diarrhea (≥3 soft, loose or watery stools per day for at least 2 consecutive days or ≥8 soft or loose stools in 48 hours) and a positive stool test for C. difficile toxin; and 2. Age ≥ 18; and 3. Written informed consent obtained  The presence of human immunodeficiency virus (HIV) infection with a CD4 count of less than 240 2. Pregnancy 3. GI Bleeding 4. Acute coronary syndrome
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 1.0-999.0,  Malaria Age ≥ 12 months P. vivax or P. falciparum mono-infection or P. vivax / P. falciparum mixed infection Presence of axillary temperature ≥ 37.5°C or history of fever during the past 24 hrs Able to tolerate oral medication Able and willing to comply with the study protocol for the duration of the study Informed consent from the patient or from a parent or guardian in the case of children  Bodyweight ≤5kg Presence of general danger signs in children aged under 5 years or signs of severe malaria in any patient according to the definitions of WHO Presence of severe malnutrition Acute anaemia <8g/dL Regular medication, which may interfere with antimalarial pharmacokinetics History of hypersensitivity reactions or contraindications to any of the drug(s) tested or used as alternative treatment(s) A positive pregnancy test or lactating
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Nausea Emesis Elective surgery Age 18-99 Patients who are capable to provide informed consent and answer questions in English For FA patients: Planned neuraxial anesthesia + nerve block for postsurgical analgesia For TSA patients: Planned brachial plexus nerve block + either general anesthesia or IV sedation  Incapable to provide informed consent Contraindications for regional or LMA anesthesia (anticoagulation, infection at injection site) Anticipated difficult airway Body mass index>35 Anticipated surgical procedure time less than 1 hour or more than 4 hours History of severe postoperative nausea and/or vomiting American Society of Anesthesiologists physical status classification >3 Neuropathy Pregnant or nursing women Chronic opioid use (daily use of opioids one month prior to surgery/ patients requiring chronic pain interventions)
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Diarrhea or more unformed stools in 24 hours Male and female subjects between 18 and 80 years old Signed informed consent  Subjects with serum ALT more than 5ULN or serum Cr more than 442umol/L Subjects are pregnant now, likely to become pregnant Subjects, who in the opinion of the Investigator, are not suitable candidates for enrollment
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Coronary Syndrome Subject with compatible symptoms with an acute coronary syndrome, for at least 15 minutes and not older than 3 hours (eg discomfort, tightness or chest pain, pain radiating to the left arm or two arms, pain in the jaw, pain in the back / neck / stomach, breathlessness , cold sweats, nausea / vomiting , dizziness ) Man or woman Patient Did not receive heparin or low molecular weight heparin (LMWH ) before the initial blood sample  Patient Agreeing to participate in the study and who signed an informed consent  Minor or major patient trust Patient Not having signed informed consent (refusal , physical or mental disability ... ) Patient Who received anticoagulation before carrying blood samples Patient With a progressive septic processes , neoplasia undergoing treatment, dialyzed kidney failure, a history of surgery or coronary angioplasty less than six months Transplanted heart, renal or hepatic heart attack Subject Whose symptoms clearly eliminates acute coronary syndrome ( penetrating trauma, traumatic injury by crushing ... ) Patient Died between the time of and arrival in the cardiology intensive care ( SIC ) Patient Withdrawing consent under study
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Diagnosis suspicion of nonfunctional P-NET on primary CT (i.e hypervascularity) or MRI signed informed consent  vulnerable study subjects such as described in Finnish law concerning clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Malnutrition Adult patients (≥18 years) who are able to communicate their views regarding acceptability Patients established on an oral nutritional supplement, being prescribed 1-2 ONS providing at least 300kcal/day Patients expected to require oral nutritional supplementation for at least 2 further weeks Informed consent obtained  Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study Patients requiring a milk free Patients with medical or dietary contraindication to any feed ingredients (see appendix 2 of protocol for full list) Patients with significant renal or hepatic impairment Patients with dysphagia requiring stage 1,2 or 3 thickened fluids Patients with uncontrolled inflammatory bowel disease or previous bowel resection with ongoing gastrointestinal symptoms
Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Healthy Normal health status (as determined by the Investigator review of medical history and blood donor physical exam) Meet FDA, American Association of Blood Banks (AABB), and site guidelines for blood donation or apheresis platelet donation Complete blood count (CBC) and serum chemistry values within established reference ranges or within guidelines as above Pre-donation platelet count of more than 150×10^9 platelets/L Negative blood donor screening test panel for Human Immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human T-Lymphotropic virus (HTLV), syphilis, and West Nile virus (WNV) Male and female subjects of childbearing potential must agree to use a medically acceptable method of contraception throughout the study. A barrier method of contraception must be included, regardless of other methods Signed and dated informed consent form  Clinically significant acute or chronic disease (as determined by the Investigator) Pregnant or nursing females Male or female subjects of childbearing potential not using effective contraception Disease states or conditions that preclude blood donation or apheresis platelet donation per AABB reference standards Treatment with aspirin or aspirin-containing medications within 7 days of apheresis or treatment with non-steroidal anti inflammatory drugs (NSAID), anti-platelet agents or other drugs affecting platelet viability within 3 days of apheresis (e.g. ibuprofen or other NSAIDs) Subject received platelet inhibitor within 14 days of donation (e.g. clopidogrel, ticlopidine) Splenectomized subjects History of known hypersensitivity to indium or chromium Participation in another clinical study currently or within the past 28 days